ECM
SLS icon

Element Capital Management’s SELLAS Life Sciences SLS Stock Holding History

Element Capital Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-107
Closed -$93K – 89
2017
Q2 		$93K Buy
+107
New +$93.1K 0.02% 128

Other funds holding SLS

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Element Capital Management's SLS Position: Q3 2017 in Review

Element Capital Management sold out of SELLAS Life Sciences (SLS) in Q3 2017, closing a stake of 107 shares — an estimated $93K sold.

Element Capital Management first reported a position in SLS in Q2 2017 and held it in 1 quarter. The position peaked at $93K in Q2 2017. 28 funds tracked by Wall St. Rank hold SLS as of Q3 2017.

  • Element Capital Management reported no remaining SELLAS Life Sciences position as of Q3 2017 after selling out during the quarter.
  • Element Capital Management sold 107 SELLAS Life Sciences shares in Q3 2017, an estimated $93K.
  • Element Capital Management first reported a position in SELLAS Life Sciences in Q2 2017 and held it in 1 quarter.
  • Element Capital Management's SELLAS Life Sciences position peaked at $93K in Q2 2017.
  • 28 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2017.

Based on Element Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.